Windlas Biotech (NSE:WINDLAS) Total Payout Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
88 GF Score
Price ₹1,109.45
GF Value ₹992.72
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Windlas Biotech Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Windlas Biotech's current Total Payout Ratio is .

Windlas Biotech Total Payout Ratio Related Terms

Windlas Biotech Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Total Payout Ratio Chart

Windlas Biotech Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only - - - - -

Windlas Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NSE:WINDLAS vs ZTS: Total Payout Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windlas Biotech Total Payout Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's Total Payout Ratio falls into.


NSE:WINDLAS
88GF Score
Windlas Biotech Ltd NSE:WINDLAS
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Windlas Biotech's Total Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 40.44 + -121.56) / 664.56
=0.12

Windlas Biotech's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- ( + + ) / 176.53
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be overvalued. The current stock price of ₹1,109.45 is trading 11.8% above its estimated GF Value™ of ₹992.72. GuruFocus considers Windlas Biotech to be Modestly Overvalued.

Key valuation signals for NSE:WINDLAS:

  • Total Payout Ratio:
  • GF Value™: ₹992.72 vs. price of ₹1,109.45 (11.8% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
88GF Score

Get the complete analysis for NSE:WINDLAS

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,109.45
Price
₹992.72
GF Value